266 related articles for article (PubMed ID: 33641862)
21. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
22. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of
Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M
Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
26. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
27. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
28. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
29. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
30. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
32. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Khodier M; Gadó K
Physiol Int; 2023 Sep; 110(3):227-250. PubMed ID: 37651280
[TBL] [Abstract][Full Text] [Related]
33. The roles of sex and genetics in the MPN.
Moliterno AR; Braunstein EM
Int Rev Cell Mol Biol; 2022; 366():1-24. PubMed ID: 35153002
[TBL] [Abstract][Full Text] [Related]
34. Leukocytosis and MPNs: Where do we stand?
Coltoff A
Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
[TBL] [Abstract][Full Text] [Related]
35. Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.
Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Shin KS; Jo DY
Intern Med; 2022 Dec; 61(23):3483-3490. PubMed ID: 35527026
[TBL] [Abstract][Full Text] [Related]
36. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2012 Jan; 53(1):123-9. PubMed ID: 21806350
[TBL] [Abstract][Full Text] [Related]
37. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
38. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
39. Inheritance of the chronic myeloproliferative neoplasms. A systematic review.
Ranjan A; Penninga E; Jelsig AM; Hasselbalch HC; Bjerrum OW
Clin Genet; 2013 Feb; 83(2):99-107. PubMed ID: 23094849
[TBL] [Abstract][Full Text] [Related]
40. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
